Alzheimer's Drug Zervimesine Secures US Patent Protection Through 2050
Cognition Therapeutics patents a stable form of CT1812, advancing its Alzheimer's and dementia drug toward registrational trials.
Summary
Cognition Therapeutics has received a US patent notice covering a crystalline form of Zervimesine (CT1812), its lead drug for Alzheimer's disease, dementia with Lewy bodies, and geographic atrophy. The patent protects the drug's composition, production process, and therapeutic uses through 2045, potentially extending to 2050. This more stable formulation is expected to be used in upcoming registrational trials for DLB psychosis, following FDA discussions in May 2026. Zervimesine has already completed Phase 2 studies across multiple age-related brain conditions and is currently being evaluated in the START study targeting mild cognitive impairment and early Alzheimer's disease. The patent milestone strengthens the company's commercial position as it moves toward late-stage clinical development.
Detailed Summary
Cognition Therapeutics has reached a significant milestone in its effort to bring a new Alzheimer's and dementia treatment to market. The US Patent and Trademark Office issued a Notice of Allowance for a patent covering a polymorphic crystalline form of Zervimesine, also known as CT1812. The patent offers protection through 2045, with a possible extension to 2050, covering the drug's composition, manufacturing method, and therapeutic applications.
Zervimesine targets age-related degenerative brain disorders including Alzheimer's disease, dementia with Lewy bodies, and geographic atrophy — a leading cause of vision loss linked to neurodegeneration. The newly patented crystalline form is claimed to offer superior chemical and thermodynamic stability, which can improve consistency in manufacturing and drug delivery, potentially leading to better clinical outcomes.
The drug has completed Phase 2 clinical studies across multiple conditions, and an ongoing Phase 2 study called START is evaluating it in patients with mild cognitive impairment and early Alzheimer's disease. Cognition Therapeutics held discussions with the FDA in May 2026 regarding its registrational program and plans to use this stable formulation in upcoming registrational trials focused on DLB psychosis.
For those interested in brain longevity, this development is meaningful. Alzheimer's and Lewy body dementia are among the most devastating conditions affecting healthspan in older adults, and very few disease-modifying treatments currently exist. A drug candidate with Phase 2 data across multiple neurodegeneration indications represents a potentially important addition to the pipeline.
Caveats remain significant. Patent allowance and positive Phase 2 data do not guarantee regulatory approval or clinical efficacy at scale. Registrational trials are still ahead, and results could differ from earlier studies. Readers should monitor upcoming trial data before drawing conclusions about Zervimesine's real-world impact.
Key Findings
- Zervimesine (CT1812) patent granted, covering Alzheimer's, Lewy body dementia, and geographic atrophy through 2045.
- New crystalline form offers improved chemical stability, potentially enhancing drug manufacturing and delivery consistency.
- Phase 2 trials completed in multiple neurodegeneration conditions; registrational trials for DLB psychosis are planned.
- FDA discussions held in May 2026 to outline the registrational program pathway for Zervimesine.
- START Phase 2 study ongoing in mild cognitive impairment and early Alzheimer's disease patients.
Methodology
This is a news report summarizing a corporate press announcement from Cognition Therapeutics. The source, Longevity.Technology, is a credible longevity-focused publication, but the evidence basis relies on company claims rather than peer-reviewed data. No independent clinical data is presented in the article.
Study Limitations
All claims about drug stability and efficacy improvements originate from the company and have not been independently verified in this article. Phase 2 data supporting earlier studies has not been detailed here and should be reviewed in primary publications. Patent protection does not confirm clinical effectiveness or regulatory approval.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.